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A b s t r a c t
Background: Complications related to the femoral access substantially contribute to peri-procedural morbidity and mortality.
Aim: To evaluate whether the use of a collagen plug as a vascular access closure device (AngioSeal®, AS) influences complica-
tions related to the femoral access and duration of hospitalization for peripheral endovascular interventions.
Material and methods: Two hundred and one consecutive patients (59.2% male, age 48-87 years) undergoing angioplasty/stent-
ing of the internal carotid, common carotid, vertebral, subclavian, renal, iliac/femoral, innominate artery or cervical-subclavian bypass
were randomized (1 : 1 ratio) prior to the intervention to standard manual compression (MC) or AS (6 F or 8 F device used for femoral
access with 6-7 F or 8-9 F sheaths respectively). 
Results: Manual compression was used in 110 patients and AS in 91 patients. There was no difference in the use of 8-9 F and 
6-7 F sheats between  the two per treatment groups (72.5% vs. 73.6% and 27.5% vs. 26.2%, respectively). Large subcutaneous haematoma,
arteriovenous fistula, pseudoaneurysm or femoral artery occlusion requiring surgery occurred in 13.8% MC vs. 4.0% AS for 6-7 F sheaths
(p = 0.36) and in 19.7% MC vs. 7.6% AS for 8-9 F sheaths (p = 0.035). Total access site complication rate was 18.2% for MC and 6.6%
for AS (p = 0.019). Nine patients with AS (9.9%) required an additional compression dressing (≤ 12 h). Overall, AS patients were mobi-
lized earlier (2.9 ±2.4 h vs. 14.2 ±2.8 h, p = 0.001) and discharged home earlier after the intervention (33.6 ±14.16 h vs. 68.1 ±34.08 h,
p = 0.001). 
Conclusions: The use of the AngioSeal® device for femoral access closure during peripheral interventions (AngioSeal® 8 F for 
8-9 F sheath and AngioSeal® 6 F for 6-7 F sheath) significantly reduces the access site complication rate and allows earlier patient
mobilization and discharge from hospital.
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S t r e s z c z e n i e
Wstęp: Miejscowe powikłania dostępu naczyniowego przez tętnicę udową po zabiegach na tętnicach obwodowych istotnie zwięk-
szają chorobowość okołozabiegową, wydłużają czas hospitalizacji oraz mogą się przyczyniać do zwiększonej śmiertelności okołoza-
biegowej.
Cel: Ocena skuteczności stosowania zapinek naczyniowych AngioSeal® w redukcji liczby miejscowych powikłań dostępu naczy-
niowego, skracaniu czasu do uruchomienia i czasu hospitalizacji po przezskórnych interwencjach w naczyniach obwodowych.
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Background
Local complications at the site of vascular access such
as large subcutaneous haematoma, pseudoaneurysm, arte-
riovenous fistula, ischaemia of the limb or local infection
complicating percutaneous cardiovascular interventions
significantly increase periprocedural morbidity, prolong the
hospitalization period and may affect periprocedural mor-
tality [1]. 
Current coronary interventions are frequently com-
pleted with the implantation of vascular closure device
instead of using conventional hemostasis (removal of the
sheath after 4-6 h followed by compression dressing for
6-8 h), which allows rapid cessation of bleeding from 
the arterial access and earlier patient mobilization. The
AngioSeal® 6 F vascular closure device is frequently used
to control local haemostasis (femoral artery) after coro-
nary interventions (6 F). However, there are no systemat-
ic analyses regarding the application of this device for
peripheral interventions. Moreover it should be noted that
this peripheral procedure usually requires vascular access
with the use of a larger (i.e. 8-9 F) cannula. 
Aim
The aim of the study was to evaluate the efficacy of
the 6 F and 8 F vascular closure device AngioSeal® in the
reduction of local complications related to vascular access
(femoral artery) and its influence on the timing of patient
mobilization and hospital discharge after percutaneous
interventions on carotid and peripheral arteries (femoral
access with 6-9 F cannula).
Material and methods
Two hundred and one consecutive patients between
48 and 87 years of age (59.2% male, mean 66.9 ±8 years)
undergoing percutaneous interventions on carotid, 
vertebral or peripheral arteries (internal carotid artery 
(n = 140), comon carotid artery (n = 3), vertebral artery 
(n = 32), iliac/femoral atery-contralateral access (n = 9),
subclavian artery (n = 12), renal artery (n = 2), innominate
artery (n = 2) or cervical-subclavian bypass) was random-
ized (1 : 1 ratio). Seven of the 98 patients (7%, 48-87 years
of age, mean 66.85 ±8 years) randomized prior to the pro-
cedure to the AngioSeal® device had angiographic con-
traindications to the use of this device (arterial puncture at
the site of common iliac artery bifurcation, diffused athero -
sclerosis of the punctured artery, vessel diameter < 5 mm)
and thus required conventional haemostasis (Figures 1-2).
Therefore the MC group (manual compression-removal of
the vascular sheath from the femoral artery after 4-6 h fol-
lowed by compression dressing for 6-8 h) included finally
110 patients  and the AS group consisted of 91 patients.
There was no difference between groups in terms of sex or
age (AS – 58.2% male, 66.8 ±8 years of age, MC – 60.0%
male, 66.7 ±9 years of age). Patient characteristics are pre-
sented in Table 1. The 6 F closure device was used after
femoral artery cannulation with 6 F (n = 24) or 7 F (n = 1)
sheaths and an 8 F device was applied after cannulations
with 8 F (n = 65) or 9 F (n = 1) introducers. All patients (AS
and MC) were on dual antiplatelet therapy (aspirin 75 mg +
+ clopidogrel 75 mg) and unfractionated  heparin was used
during the procedure to achieve activated coagulation time
(ACT) > 250 s. Oral anticoagulant therapy was stopped before
the procedure in all patients on chronic treatment with
acenocoumarol/warfarin (n = 2 for AS – 2.2%, n = 1 for MC
– 0.9%) to obtain INR < 1.4 allowing an elective percutaneous
intervention. Subcutaneous injections of low molecular
weight heparin were stopped for at least 12 h prior to the
procedure and after the procedure in all patients on this type
of therapy (n = 4 for the AS group; n = 1 for the MC group,
0.9%). Mean INR value in the AS group before the procedure
was 1.07 ±0.16 vs. and in the MC group 1.06 ±0.13 (p = 0.79).
Mean platelet count (PLT) was 212.48 ±57.05 in the AS group
and 218.48 ±61.193 in the MC group (p = 0.532).
Local conditions at the site of vascular access were
assessed (physical examination and dopler duplex was
needed) directly after the implantation of the device, 1-3 h
after the procedure, and at discharge from the hospital.
Materiał i metody: Do standardowej kompresji manualnej (manual compression – MC) vs zapinki AngioSeal® (AS, 6 F i 8 F odpo-
wiednio dla dostępu kaniulą 6–7 F i 8–9 F) zrandomizowano (1 : 1) 201 chorych w wieku 48–87 lat (średnio 66,9 ±8 lat, 59,2% męż-
czyzn) poddawanych przezskórnej angioplastyce tętnic obwodowych (szyjnej wewnętrznej, szyjnej wspólnej, kręgowej, biodrowej
lub udowej, podobojczykowej, nerkowej, pnia ramienno-głowowego, pomostu szyjno-podobojczykowego). U 7 chorych zrandomizo-
wanych do grupy AS (7,1%) nie było warunków anatomicznych do założenia zapinki naczyniowej. Kaniule 8–9 F zastosowano w 73,6%
zabiegów w grupie MC vs w 72,5% zabiegów w grupie AS (p = 0,986).
Wyniki: Łącznie ostre niedokrwienie kończyny, tętniak rzekomy, rozległy krwiak podskórny, przetoka tętniczo-żylna wystąpiły
istotnie częściej w grupie MC niż w AS (18,2% vs 6,6%, p = 0,019), po kaniulacji 8–9 F (19,7% MC vs 7,6% AS) (p = 0,035). Po zabie-
gu chorzy z AS byli uruchomieni po 1–12 godzinach (średnia: 2,90 ±2,4), a MC 8,6–19,3 godziny (średnia: 14,18 ±2,28) (p < 0,001). Dzie-
więciu pacjentów z AS (9,9%) wymagało dodatkowo opatrunku uciskowego przez 6–12 godzin. Chorych z grupy MC wypisano ze
szpitala 24–240 godzin po zabiegu (średnia: 68,1 ±34,08) vs AS po 24–72 godzinach (średnia: 33,6 ±14,16) (p = 0,001). 
Wnioski: Zamknięcie dostępu naczyniowego zapinkami naczyniowymi AngioSeal® 6 F i 8 F po przezskórnych interwencjach na
tętnicach obwodowych przez tętnicę udową po kaniulacji 6–9 F jest bezpieczne, zmniejsza ryzyko wystąpienia powikłań miejsco-
wych oraz skraca czas unieruchomienia i hospitalizacji. 
Słowa kluczowe: AngioSeal®, zapinki naczyniowe, powikłania dostępu naczyniowego, zamykanie dostępu naczyniowego przez tęt-
nicę udową
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Statistical analysis
Qualitative variables are shown as percentages and
number of cases in each group. Quantitative variables are
presented as mean ± standard deviation and minimal and
maximal values. Chi-square test or Fisher’s exact test was
used to compare qualitative variables, where appropriate.
Quantitative variables were compared using Student’s 
t-test or Mann-Whitney U test, when appropriate. Nor-
mality of distribution was assessed with the Shapiro-Wilk
test, and Levene test was used to assess the equality of
variances. 
Analyses were performed with the R software (version
2.13.0) and with two-sided significance level of α = 0.05.
Results
The following complications occurred in the MC 
(n = 110) vs. the AS (n = 91) group: acute lower limb isch -
aemia requiring surgical intervention – 1 (0.9%) vs. 0 (0%)
(p = 1.0); pseudoaneurysm – 5 (4.5%) vs. 0 (0%) (p = 0.065);
arteriovenous fistula – 1 (0.9%) vs. 0 (0%) (p = 1.0); large
subcutaneous haematoma – 13 (11.8%) vs. 6 (6.6%) 
(p = 0.235). Complications after the use of 6 F-9 F intro-
ducers in patients from the MC and the AS group are pre-
sented in Table 2 A.
Complications including large subcutaneous hae -
matoma (> 10 cm according to the American College of
Cardiology/American Heart Association) [2], arteriovenous
Fig. 1. Angiographic contraindications to the use of AngioSeal® (examples): A-B – significant atherosclerosis of
a common femoral artery in the puncture site, C-D – puncture of a femoral artery bifurcation, E – puncture of
a deep femoral artery
Ryc. 1. Przykłady angiograficznych przeciwwskazań do założenia zapinki naczyniowej AngioSeal®: A–B – zmiany
miażdżycowe w miejscu nakłucia tętnicy udowej wspólnej, C–D – nakłucie w bifurkacji tętnicy udowej, E – nakłu-
cie tętnicy głębokiej uda
A B C D E
Fig. 2 A-D. Lack of angiographic contraindications to the use of AngioSeal®
Ryc. 2 A–D. Brak angiograficznych przeciwwskazań do założenia zapinki AngioSeal®
A B C D
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fistula, pseudoaneurysm, and acute lower limb ischaemia
occurred in 13.8% of patients after MC vs. 4.0% after AS
(p = 0.36) for cannulation with 6-7 F sheaths and in 19.7%
after MC vs. 7.6% after AS (p = 0.035) for cannulation with
8-9 F sheaths (Table 2 B). In total, complications includ-
ing acute limb ischaemia, pseudoaneurysm, large subcu-
taneous haematoma, and arteriovenous fistula occurred
in 20 patients after MC (18.2%) vs. 6 patients after AS
(6.6%) (p = 0.019) irrespective of the sheath size (Table 2 B).
Pseudoaneurysms found after MC required blood trans-
fusion in 1 case, thrombin injection in 1 case and ultra-
sound-guided mechanical compression in 4 cases. There
were no cases of pulmonary embolism or infection of the
access site observed in any of the groups. 
Mean decrease of haematocrit (HCT) values after the
procedure in the AS vs. the MC group was 3.93 ±1.95% vs.
4.19 ±2.53% (p = 0.4289). Mean decrease of haemoglobin
(Hgb) level in the AS vs. the MC group was 1.37 ±0.62 vs.
1.49 ±0.89 (p = 0.288). 
Patients with AS were mobilized after 1-12 h (mean 2.90
±2.4 h) vs. 8.66-19.33 h (mean 14.18 ±2.28 h) for MC 
(p < 0.001) (Figure 3). Nine patients with AS (9.9%) required
an additional compression dressing for 6-12 h due to pro-
longed bleeding from the access site despite the collagen
plug use. This was associated with occurrence of a large
subcutaneous haematoma in 6 cases (5 for the 8 F device
and 1 for the 6 F device, 4.4%). Patients who received MC
Parameter AS Group MC Group Value of p
(n = 91) (n = 110)
Age [years] 66.9 ±8 66.7 ±8 0.859
Men 58.2% (n = 53) 60.0% (n = 66) 0.800
Hypertension 94.5% (n = 86) 93.6% (n = 103) 0.795
Hyperlipidaemia 82.4% (n = 75) 87.3% (n = 96) 0.336
Diabetes 24.2% (n = 22) 24.6% (n = 27) 0.986
Previous PCI/PTA 24.2% (n = 22) 33.6% (n = 37) 0.142
BMI [kg/m2] 27.7 ±4.5 27.0 ±4.4 0.324
Peripheral arterial 10.9% (n = 10) 20.0% (n = 22) 0.100
disease of the 
lower extremities
Tobacco smoking 27.4% (n = 25) 30.0% (n = 33) 0.693
INR before 1.07 ±0.16 1.06 ±0.13 0.79
the procedure
APTT before 31.504 ±4.5 32.71 ±5.3 0.090
the procedure 
PLT before  212.48 ±57.05 218.48 ±61.193 0.532
the procedure
Chronic renal 27.4% (n = 25) 22.7% (n = 25) 0.438
failure
Table 1. Baseline characteristics of patients
Tabela 1. Charakterystyka pacjentów
PCI – percutaneous coronary intervention, PTA – percutaneous 
transluminal angioplasty, BMI – body mass index, INR – international
normalized ratio, APTT – activated partial thromboplastin time, 
PLT – thrombocytes
A
Group Sheath size Large Pseudoaneurysm Arteriovenous Acute lower Total number Number of
subcutaneous fistula limb ischaemia of local complications
haematoma complications in the group
MC (n = 110) 6 F Sheath (n = 29) 6.9% (n = 2) 3.44% (n = 1) 3.44% (n = 1) 0% 13.8% (n = 4) 20 (18.2%)
7 F Sheath (n = 0) 0% 0% 0% 0% 0%
8 F Sheath (n = 80) 12.5% (n = 10) 5% (n = 4) 0% 1.25% (n = 1) 18.8% (n = 15)
9 F Sheath (n = 1) n = 1 0% 0% 0% n = 1
AS (n = 91) 6 F Sheath (n = 24) 4.2% (n = 1) 0% 0% 0% 4.2% (n = 1) 6 (6.6%)
7 F Sheath (n = 1) 0% 0% 0% 0% 0%
8 F Sheath (n = 65) 7.7% (n = 5) 0% 0% 0% 7.7% (n = 5)
9 F Sheath (n = 1) 0% 0% 0% 0% 0%
B
Complications in the Complications in the Complications in the Complications in the 
MC group for 6-7 F sheath AS group for 6-7 F sheath MC group for 6-7 F sheath AS group for 6-7 F sheath
13.8% (n = 4) 4.0% (n = 1) 19.7% (n = 16) 7.6% (n = 5)
p = 0.36 p = 0.035
Total number of complications in the MC group Total number of complications in the AS group
18.2% (n = 20) 6.6% (n = 6)
p = 0.019
Table 2 A-B. Complications in the AngioSeal® group vs. manual compression group in relation to the arterial
sheath size
Tabela 2 A–B. Powikłania w grupie z zapinkami AngioSeal® vs z konwencjonalną hemostazą z uwzględnieniem
rozmiaru kaniuli tętniczej
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were discharged from the hospital after 24-240 h (mean:
68.1 ±34.08 h) vs. 24-72 h (mean: 33.6 ±14.16 h) for AS 
(p = 0.001) (Figure 4). 
In one case, implantation of the 8 F AngioSeal® device
was complicated by distal mobilisation of the device
anchor with the blood flow. There were no symptoms of
limb ischaemia and the access site was controlled with
standard manual compression.
Discussion
Several prior studies demonstrated the efficacy and
safety of the AngioSeal® vascular closure device for coro-
nary interventions with a 6 F vascular access. In contrast,
the present study systematically assessed the use of the
6 F and 8 F AngioSeal® vascular closure device for interven-
tions on peripheral arteries via femoral access (6 F de vice
after 6-7 F sheats and 8 F device after 8-9 F sheats). Most
of the procedures involved an internal carotid artery 
(n = 140, 69%) which required an 8 F and 9 F cannula to
allow the use of the neuroprotective systems. 
According to the AS instruction for use and pior reports
we have avoided the use of the vascular closure device in
the case of severly diseased arteries, especially when the
vessel diameter was below 5 mm, if significant athero-
sclerotic lesions were localized within the distance of 5 mm
from the puncture site or when they caused a 40% reduc-
tion of the vascular lumen (less advanced changes were
a relative contraindication) [3]. The AngioSeal® device was
also not used in the case of a femoral artery bifurcation
or a superficial/deep femoral artery puncture [3]. Impor-
tantly  angiography of the femoral artery was performed
in each case in our study prior to the AngioSeal® use.
Femoral angiogram was assessed for the presence of sig-
nificant lesions of the arterial wall at the site of the punc-
ture. In the case of contraindications to the use of the
device (7/98 patients randomized to AngioSeal® – 7.0%)
a classic compression dressing was applied. Longer time
of hospitalization of patients after manual compression
was caused not only by the longer time of immobilization,
but also by more frequent and more severe complications
such as pseudoaneurysms and lower limb ischaemia. On
the other hand successful haemostasis was not obtained
in all of the patients who received the AngioSeal® device.
Nine patients in the AngioSeal® group still required the
use of a classic compression dressing due to prolonged
bleeding and six of them developed a large subcutaneous
haematoma. In 1 case implantation of the AngioSeal®
device was complicated by a rupture of a Dexon suture
with intra-arterial distal dislocation of the device anchor.
In this patient manual compression was performed and
subsequently a full dose of low molecular weight heparin
(1 mg/kg s.c. every 12 h) was administrated for 3 days to
prevent lower limb ischaemia (embolisation by the poly-
meric fragment – 1 mm × 2 mm × 10 mm). There were no
symptoms of ischaemia during the hospitalization or dur-
ing ambulatory visits which followed. 
One patient from the MC group cannulated with an 
8 F introducer who underwent successful angioplasty of
the internal carotid artery presented symptoms of acute
lower limb ischaemia 6 h after the procedure caused by
thrombosis of the superficial and deep femoral artery.
The patient had diffused atherosclerotic lesions in
femoral and iliac arteries. She required two emergency
surgical interventions: the first one consisted of trombi
removal followed by angioplasty with implantation of
an arterial patch; the second one wich took place after
reccurence of thrombosis in the index location, was
a hybrid procedure consisting of angioplasty of the com-
mon iliac artery, reopening of the superficial femoral
artery with stent implantation and implantation of
venous femoro-femoral bypass which led to the resolu-
tion of symptoms. 
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Fig. 3. Time of post-procedural mobilization of
patients with AngioSeal® (AS) vs. manual com-
pression (MC)
Ryc. 3. Czas uruchomienia pacjentów, u których
stosowano zapinkę AngioSeal® (AS) vs hemostazę
konwencjonalną (MC)
14.2 ±2.3 h2.9 ±2.4 h
p < 0.001
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Fig. 4. Duration of post-procedural hospitalization
after percutaneous intervention in patients with
AngioSeal® (AS) vs. manual compression (MC)
Ryc. 4. Czas pozabiegowej hospitalizacji pacjentów,
u których stosowano zapinkę AngioSeal® (AS) vs
hemostazę konwencjonalną (MC)
68.1 ±34.1 h
33.6 ±14.2 h
p < 0.001
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Several cases of acute and chronic limb ischaemia relat-
ed to the AngioSeal® device implantation have been
described previously. These occurred after implantation of
the device in the atherosclerotically changed vessel or in
the superficial femoral artery, after dissection of the ath-
erosclerotic plaque or after thrombosis leading to occlu-
sion of the artery [4-9]. In some cases a collagen plug was
found intra-operatively in the lumen of the superficial
femoral artery [4, 10]. These patients required percutaneous
[11] or surgical [4-6] interventions due to limb ischaemia.
All of the procedures succesful and no symptoms of
ischaemia were observed during follow-up were reported.
There is also a description of a patient in whom elements
of the AngioSeal® device did not undergo biodegradation
and who had a critical stenosis of the vessel caused by
excessive proliferation of the connective tissue at the site
of the intravasculary located anchor of the device [9]. An
attempted percutaneous intervention led to distal emboliza-
tion and occlusion of the trifurcating popliteal artery. The
patient underwent a successful surgical procedure and did
not present symptoms of ischaemia during subsequent
observation [10]. Less severe symptoms of ischaemia includ-
ing claudication of the lower limb after the AngioSeal®
device implantation were also described [6]. In this case the
patient remained under ambulatory follow-up because of
the lack of symptoms of severe ischaemia. The symptoms
were milder and eventually resolved with the end of
biodegradation of the intravascular elements of the
AngioSeal® device. The patient did not require interven-
tional treatment [6]. Most of the studies report similar to
ours frequency of local complications for the AngioSeal®
device such as large subcutaneous haematoma, pseudoa-
neurysm, arteriovenous fistula, and limb ischaemia in com-
parison to the use of classic compression dressing [3, 12-18].
In one of the studies there was a tendency towards high-
er frequency of local complications in female patients, which
was probably related to the lower diameter of the femoral
artery in comparison to male patients [19]. Retrospective
series by Assali et al. [20] and Dangas et al. [21] suggested
a higher frequency of local complications after coronary
interventions in patients who received vascular closure
devices (including the AngioSeal® device) in comparison to
patients who had a compression dressing, but the number
of patients with the AngioSeal® device was approximately
4-fold [20] or even over 13-fold [21] lower than patients with
conventional haemostasis. Also, implantation of the
AngioSeal® device was not routinelly preceded in by an -
giography of the ipsilateral femoral artery. In a large group
of patients, Carey et al. [22] reported that the use of the
AngioSeal® device increased the risk of limb ischaemia in
comparison to manual compression. However, in contrast
to our strategy, angiography of the femoral artery was not
performed routinely before implantation of the AngioSeal®
device and therefore interpretation of the results of this
study should be done with caution. 
Other AS complications such as pseudoaneurysms
resolved spontaneously [7] after manual compression or
were successfully treated with surgery in some patients.
Koreny et al. [23] in 2004 and Biancari et al. [24] in 2009
performed a meta-analysis of approximately 30 prospec-
tive, randomized studies assessing the efficacy and safe-
ty of different types of vascular closure devices (including
the AngioSeal®) in comparison to conventional haemosta-
sis for the closure of femoral access, mainly after coronary
interventions, and found a tendency towards higher fre-
quency of local complications related to the use of these
vascular devices (including the AngioSeal®). Interpretation
of the results of these studies is limited by high hetero-
geneity of the compared groups, differences in end-point
definitions (regarding for example the size of a large
haematoma), the use of an older generation of closure
devices in some of the studies, and exclusion of patients
with high risk of local complications such as obese patients.
Most of the studies included patients cannulated using 
a 6 F introducer, while patients in our study were mainly
(73%) cannulated using an 8 F or 9 F introducer. In addi-
tion it should be noted that the use of AngioSeal® (like any
other interventional device) involves a learning curve, and
in the present study AngioSeal® was used by operators
with a major prior experience.  
It should be noted that resorpti on of the AngioSeal®
device elements takes around 90 days, and during that
period a vascular access in the proximity of the device
should be avoided (according to the manufacturer’s rec-
ommendations). Some studies suggest that a 0.5-1.0 cm
margin should be used [7, 25] if the index artery is used
for vascular access within 90 days.
In the case of surgery, a vascular surgeon should pay
special attention while operating in the proximity of the
AngioSeal® device implanted into the femoral artery to avoid
involuntary translocation of the device elements, which can
lead to severe complications including limb ischaemia, as
demonstrated in the case described by Ponton et al. [6]. 
Trans radial access is currently considered as a safer approach
leading to lower frequency of bleeding complications and it
is used with increasing frequency for coronary interventions
[26]. However, some endovascular interventions, mainly
those on carotid arteries, require larger diameters of can-
nula to allow introduction of neuroprotective systems and
therefore they currently require  the femoral access.
Conclusions
We found that the 6 F and 8 F AngioSeal® device can
be safely used to close the femoral access during periph-
eral interventions involving after cannulation with 6-7 F or
8-9 F introducers, respectively. We also showed that vas-
cular closure device reduces the risk of peri-procedural local
complications after femoral access and leads to shorten-
ing of the immobilization period and hospitalization time
shortening.
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